Related Experiment Video
Updated: Dec 24, 2025
08:50
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
24.2K
Hepatorenal Syndrome.
1Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medical Campus, Aurora, USA.
International Journal of Clinical Medicine
|April 15, 2020
Summary
Hepatorenal syndrome (HRS) management focuses on reversing underlying mechanisms like portal hypertension. Liver transplantation is definitive, while therapies like terlipressin aim to improve transplant eligibility.
Area of Science:
- Hepatology and Nephrology
- Critical Care Medicine
Background:
- Hepatorenal syndrome (HRS) is a severe complication of advanced liver disease.
- It involves complex pathophysiological mechanisms including portal hypertension, splanchnic vasodilation, and renal vasoconstriction.
- HRS significantly increases morbidity and mortality in patients with liver conditions.
Purpose of the Study:
- To review current treatment strategies for hepatorenal syndrome.
- To highlight the role of pharmacologic and non-pharmacologic interventions.
- To identify areas where further research is needed to improve patient outcomes.
Main Methods:
- Literature review of existing studies on hepatorenal syndrome treatments.
- Analysis of pharmacologic therapies including terlipressin, norepinephrine, vasopressin, midodrine, and octreotide.
- Evaluation of non-pharmacologic interventions such as artificial hepatic support devices, renal replacement therapy, and transjugular intrahepatic portosystemic shunt (TIPS).
Main Results:
- Liver transplantation remains the preferred definitive treatment for HRS.
- Terlipressin with albumin is the leading pharmacologic therapy; alternatives exist where terlipressin is unavailable.
- For Type II HRS, midodrine plus octreotide offers an outpatient treatment option.
- Non-pharmacologic options like hepatic support devices and renal replacement therapy have not shown improved outcomes; TIPS has limitations in Type I HRS.
Conclusions:
- Current treatments aim to reverse HRS mechanisms and prolong survival for liver transplantation.
- Careful monitoring is crucial during vasoconstrictor therapy to prevent adverse effects.
- Further research is essential to enhance the management and outcomes for patients with hepatorenal syndrome.
Related Concept Videos
01:24Nephrotic Syndrome I : Introduction
409
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
409
01:29Acute Kidney Injury II: Pathophysiology
737
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
737
01:26Nephrotic Syndrome II : Assessment and Medical Management
148
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
148
01:29Acute Kidney Injury III: Clinical Manifestations
671
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
671
01:26Kidney Transplant II: Surgical Procedure
223
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
223
01:24Nephrotic Syndrome III : Nursing Management
224
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
224